All In Biotech

Drug Trial Radar · NCT07284979

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,270 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,270

Actual

Start

Dec 30, 2025

Primary completion

Mar 2028

Study completion Apr 2028

Sponsor

Lead sponsor
KaileraIndustry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Conditions

  • Obesity

Interventions

  • RibupatideDrug

    SC Injection

  • SemaglutideDrug

    SC Injection

  • PlaceboDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Body Weight at Week 76Time frame: Baseline, Week 76

Locations

60 sites in 5 countries. Site status is shown where the registry gives one.

  • Kailera Clinical Site

    Glendale, Arizona

  • Kailera Clinical Site

    Phoenix, Arizona

  • Kailera Clinical Site

    Little Rock, Arkansas

  • Kailera Clinical Site

    Northridge, California

  • Kailera Clinical Site

    Oceanside, California

  • Kailera Clinical Site

    Hamden, Connecticut

  • Kailera Clinical Site

    Stamford, Connecticut

  • Kailera Clinical Site

    Orange City, Florida

  • Kailera Clinical Site

    Albany, Georgia

  • Kailera Clinical Site

    Chicago, Illinois

  • Kailera Clinical Site

    Skokie, Illinois

  • Kailera Clinical Site

    Newton, Kansas

  • Kailera Clinical Site

    Shreveport, Louisiana

  • Kailera Clinical Site

    Farmington Hills, Michigan

  • Kailera Clinical Site

    Missoula, Montana

  • Kailera Clinical Site

    Las Vegas, Nevada

  • Kailera Clinical Site

    Albany, New York

  • Kailera Clinical Site

    Morehead City, North Carolina

  • Kailera Clinical Site

    Morrisville, North Carolina

  • Kailera Clinical Site

    Norman, Oklahoma

  • Kailera Clinical Site

    East Greenwich, Rhode Island

  • Kailera Clinical Site

    North Charleston, South Carolina

  • Kailera Clinical Site

    Spartanburg, South Carolina

  • Kailera Clinical Site

    Brownsville, Texas

  • Kailera Clinical Site #1

    San Antonio, Texas

  • Kailera Clinical Site #2

    San Antonio, Texas

  • Kailera Clinical Site

    Manassas, Virginia

  • Kailera Clinical Site

    Richmond, Virginia

  • Kailera Clinical Site

    Bruce, Australian Capital Territory, Australia

  • Kailera Clinical Site

    Blacktown, New South Wales, Australia

  • Kailera Clinical Site

    Kanwal, New South Wales, Australia

  • Kailera Clinical Site

    Herston, Queensland, Australia

  • Kailera Clinical Site

    Morayfield, Queensland, Australia

  • Kailera Clinical Site

    South Brisbane, Queensland, Australia

  • Kailera Clinical Site

    Camberwell, Victoria, Australia

  • Kailera Clinical Site

    Montana, Bulgaria

  • Kailera Clinical Site

    Sofia, Bulgaria

  • Kailera Clinical Site

    Sofia, Bulgaria

  • Kailera Clinical Site

    Stara Zagora, Bulgaria

  • Kailera Clinical Site

    Pleven, Pleven Province, Bulgaria

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.